Ashvin Bashyam retweeted
Something I've been excited about for a long time--how we can create a way for everybody to get the clearest picture of their health, from the comfort of their own home.
@omarabudayyeh, @YRBadran, and I have been hard at work translating proteomics to be accessible to everybody. An incredible amount of research indicates that proteins are the best way to model the future of human health (although I think combining them with other data is even better...watch this space!)
I believe that @heliosforyou will be the way that we can all track our bodies, pushing back disease and letting us live younger, longer.
Also, thanks @AmyDMarcus and @theinformation for covering our story!
Introducing Helios: measuring 1,000+ protein biomarkers from a drop of blood to help you live younger, longer.
Here’s how it works:
• Self-collect blood at home with a painless, needle-free device
• We measure the proteins carrying signals from cells and organs throughout your body
• Your Helios AI agent explains your results, highlights risks, and offers personalized guidance
Proudly backed by Y Combinator and Formation VC.
Join the waitlist at myhelios.com
Ashvin Bashyam retweeted
Introducing Helios: measuring 1,000+ protein biomarkers from a drop of blood to help you live younger, longer.
Here’s how it works:
• Self-collect blood at home with a painless, needle-free device
• We measure the proteins carrying signals from cells and organs throughout your body
• Your Helios AI agent explains your results, highlights risks, and offers personalized guidance
Proudly backed by Y Combinator and Formation VC.
Join the waitlist at myhelios.com
Ashvin Bashyam retweeted
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
Ashvin Bashyam retweeted
Today, there's a strong focus on fast-follows of existing drugs. The drug programs that inspire me look different – the target is known, but we don't know how to build the drug, often requiring the dev of new tech that paves the path for more drugs.
Ashvin Bashyam retweeted
What you’re seeing at @ManifoldBio is what happens when two exponentials begin to resonate–the evolution of AI and the evolution of massively parallel molecular measurement and design.
When we started Manifold Bio with @PierceOgdenJ , @geochurch , and @slofgren, we set out to do something bold: to build an AI-first biopharma company that could map the astronomic space of molecular design against the complexity of human biology.
We had already become world leaders in the secret art of combining Machine Learning and Multiplexed Libraries, or ML². We believed this approach could be transformative to drug discovery.
AI in drug discovery has always faced one fundamental barrier: the translational gap between what works in a petri dish and what will work in a patient. We believed that closing that gap required a way to power AI models with massive-scale experimental feedback directly from living organisms.
Such a platform would be positioned to solve grand challenges in human health, including creating medicines that could cross the blood-brain barrier.
To succeed in such a challenge, it not only takes a culture of scientific boldness, but also bold partners. The boldness of the Roche team was clear from the moment we started mapping out this collaboration, both in their rigor in evaluation of the Manifold platform and the ambition we both shared in how to best leverage our approach. This is the company that has literally integrated the Genentech DNA, and charted many firsts along the way, including some of the most compelling brain-shuttling clinical data to date. It’s a privilege to combine forces to advance the frontier of brain delivery together.
This deal is fantastic validation of the power of our approach. And we’re just getting started.
The hardest problems in medicine will not be solved by incremental innovation.
They will require a fundamentally new approach that grounds AI-driven design in large-scale data from living systems.
Excited to announce our partnership with @Roche
manifold.bio/news/manifold-b…
Ashvin Bashyam retweeted
I've finally digested the data that Uniqure presented on AMT-130, their gene therapy for Huntington's disease, which just announced a positive trial readout with 75% slowing of disease progression. Here is a blog post with my take on the announcement: cureffi.org/2025/10/08/amt-1…
Ashvin Bashyam retweeted
I’m really excited to see what happens at the interface of biotech and AI over the next few years. The scale and type of data generation will be key. Gleb & crew have been building something really unique and special here. Give it a read: @glebkuz @PierceOgdenJ @slofgren
We're stil writing the @ManifoldBio story, but @ElliotHershberg just dropped a fantastic piece capturing the journey so far on his blog Century of Biology.
Ashvin Bashyam retweeted
Charles did not have a roadmap for what he envisioned but he did have two guiding principles:
1. Do something important. That is, work to develop new medicines that would address important areas of biology or medicine.
2. Do something different. Again, these cannot be exclusive. I.e., don't be different and not important. But Charles guided us to aspire to be creative in trying to find areas of biology and medicine that were not well-addressed or were not likely to be addressed soon.
Ashvin Bashyam retweeted
🇨🇳 #AusperBio announced the presentation of end-of-treatment (EOT) clinical data from its ongoing Phase IIb trial of AHB-137 in a late-breaking poster session #easl2025 prnewswire.com/news-releases…
AHB-137 is an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B virus (HBV) infection for functional cure.
16 or 24 weeks of AHB-137 treatment.
The primary endpoint, HBsAg < 0.05 IU/mL, the lower limit of quantification (LLOQ), and HBV DNA < LLOQ (10 IU/mL) at the end of treatment,
was achieved by 66% (21/32) in the 16-week arm and 75% (24/32) in the 24-week arm.
Among patients achieving the primary endpoint, >80% experienced HBsAg loss within 12 weeks, and anti-HBs seroconversion at the end of treatment was observed in 33% and 54% of subjects in the 16-week and 24-week arms, respectively.
Ashvin Bashyam retweeted
A big step forward for biomolecular ultrasound! 🔊
Congrats @bgheiles, @DMarescalab at @tudelft and collaborators! #gasvesicles
A new method reported in Science allows the generation of 3D ultrasound images of gene expression and 2D ultrasound images of capillary vessels. The approach enables fast, deep, and volumetric imaging of living opaque organs labeled with echogenic reporters.
Learn more in this week's issue: scim.ag/3R0HCXW

ALT A cross-propagating ultrasound wave exposes a thin tissue section that contains blood vessels feeding a tumor. The wave interacts with sound-scattering probes (displayed in orange gold) that are genetically expressed in cancer cells or are injected in the bloodstream to reveal capillary vessels. White contour lines indicate previously scanned tissue sections and the total volume explored by this sound-sheet microscopy technique.
Ashvin Bashyam retweeted
a personal update: in January, I'm moving to Yale to join @MCDB_Yale and to open my lab in the @WuTsaiYale Institute!
We will investigate multicellular self-organization using synbio tools to read and write developmental signals in stem cell models.
syndevbio.org/
Ashvin Bashyam retweeted
I am $30 away from $10,000 raised for cancer research through the Damon Runyon Cancer Research Foundation!
To celebrate, here’s the board game @Heleninthecloud and I made! We just got the alpha copies in the mail earlier this week and they look amazing!!
Ashvin Bashyam retweeted
Beautiful work by @omarabudayyeh and @jgooten demonstrating rapid optimization of protein fitness / activity with assisted directed evolution science.org/doi/10.1126/scie…
Ashvin Bashyam retweeted
Something new is in the cards…help me fundraise $50,000 for the Damon Runyon Cancer Research Foundation as part of the @ldtimmerman Traverse to Everest Base Camp!
If you are board this weekend, check out the new game @Heleninthecloud and I are creating to support the fundraise!
Ashvin Bashyam retweeted
Big news! 🥳🥂 In July 2025, I will be joining the faculty of University of Pennsylvania, @Penn_CBIO. The Goodman Lab for Synthetic Immunology will combine synthetic biology, genome engineering, and ML-driven functional genomics to study and manipulate primary immune cells. 🧵1/3
Ashvin Bashyam retweeted
Do LLMs really need to be so L?
That's a rejected title for a new paper w/ @Andr3yGR, @kushal_tirumala, @Hasan_Shap, @PaoloGlorioso1 on pruning open-weight LLMs: we can remove up to *half* the layers of Llama-2 70B w/ essentially no impact on performance on QA benchmarks.
1/
Ashvin Bashyam retweeted
Terrific way to start #JPM24. 2nd annual Timmerman Traverse alumni hike. Thanks Jen McNealey, TT for LSC '22 alum, for organizing. Conversations about biotech, nature, exploring, and giving back. @LS_Cares @DamonRunyon @fredhutch
Ashvin Bashyam retweeted
Extreme scenarios of AI focus on what is logically possible rather than what is physically possible.
What does physics have to say about AI risk?
1/2
Ashvin Bashyam retweeted
1/ Announcing our spinoff from @oughtinc into a public benefit corporation, our $9 million seed round, and a much more powerful Elicit!
This new Elicit takes the components of the popular literature review workflow and extends them to automate more research workflows.
































